SWOG GRANT APPLICATION FOR LOYOLA UNIVERSITY

洛约拉大学 SWOG 拨款申请

• 批准号: 3558746
• 负责人: RICHARD I FISHER
• 金额: $ 14.19万
• 依托单位: LOYOLA UNIVERSITY CHICAGO
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-01-01 至 1992-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3558746
• 关键词: acute leukemia; antibody dependent killer cell; biological response modifiers; bone marrow transplantation; cis platinum compound; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; drug metabolism; drug resistance; female reproductive system neoplasm; gastrointestinal neoplasms; head /neck neoplasm; human subject; human therapy evaluation; interleukin 2; leukocyte activation /transformation; lung neoplasms; lymphokines; lymphoma; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; platelets

Loyola University Stritch School of Medicine (LUSSOM) is applying to become a funded member of the Southwest Oncology Group (SWOG). Clinical cancer research studies will be conducted in cooperation with the other member institutions of SWOG. Studies will involve combined modality treatment of adult patients with malignant disease. The principal investigator and other LUSSOM faculty have broad experience in clinical and laboratory cancer research. LUSSOM was approved as a probationary member of SWOG on September 13, 1985 with Richard I. Fisher, M.D. as the Principal Investigator. After meeting the SWOG eligibility requirements, LUSSOM was moved to full membership status on September 26, 1986. LUSSOM is participating in SWOG in order to make significant contributions to the scientific, administrative, and patient accrual goals of the group. A total of fifteen Loyola faculty members in Hemtology/Oncology, Surgical Oncology, Radiation Oncology, Gynecologic Oncology, Urology and Pathology are now members of SWOG. LUSSOM faculty are now represented as the Chairman of the SWOG Lymphoma Committee, members of the Lung and Breast Working Committees, and Study Coordinators for twelve current or proposed SWOG clinical trials. In addition, LUSSOM has entered approximately seventy-five patients on SWOG clinical trials during its first real year of operation. Support is now requested for group participation and data management by LUSSOM.

洛约拉大学斯特里奇医学院 (LUSSOM) 是 申请成为西南肿瘤学资助会员 组（SWOG）。 将进行临床癌症研究 与 SWOG 的其他成员机构合作。 研究将涉及成人的综合治疗 患有恶性疾病的患者。 首席研究员和 其他 LUSSOM 教员在临床和 实验室癌症研究。 LUSSOM 被批准为 1985 年 9 月 13 日成为 SWOG 预备成员 理查德·I·费希尔 (Richard I. Fisher) 医学博士担任首席研究员。 后 满足 SWOG 资格要求，LUSSOM 被移动 1986 年 9 月 26 日成为正式会员。LUSSOM 是 参与 SWOG 以做出重大贡献 科学、管理和患者累积目标 团体。 洛约拉共有 15 名教职人员 血液学/肿瘤学、外科肿瘤学、放射肿瘤学、 妇科肿瘤科、泌尿科和病理科现已成为会员 的SWOG。 LUSSOM 教师现担任主席 SWOG 淋巴瘤委员会成员、肺和 乳腺工作委员会和十二个研究协调员 当前或拟议的 SWOG 临床试验。 此外，卢索姆 已将约 75 名患者纳入 SWOG 临床 在其实际运营的第一个年度进行试验。 现在支持 要求小组参与和数据管理 卢索姆。